Cargando…

Dupilumab and tezepelumab in severe refractory asthma: new opportunities

Bronchial asthma is a chronic inflammatory condition with increasing prevalence worldwide that may present as heterogeneous phenotypes defined by the T2-mediated pattern of airway inflammation T2-high and T2-low asthma. Severe refractory asthma includes a subset of asthmatic patients who fail to con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ragnoli, Beatrice, Morjaria, Jaymin, Pignatti, Patrizia, Montuschi, Paolo, Barbieri, Mariangela, Mondini, Lucrezia, Ruggero, Luca, Trotta, Liliana, Malerba, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152192/ https://www.ncbi.nlm.nih.gov/pubmed/35655942 http://dx.doi.org/10.1177/20406223221097327

Ejemplares similares

Sleep Deprivation, Immune Suppression and SARS-CoV-2 Infection
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023)

Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases
por: Ragnoli, Beatrice, et al.
Publicado: (2023)

Predictive Markers of Bronchial Hyperreactivity in a Large Cohort of Young Adults With Cough Variant Asthma
por: Malerba, Mario, et al.
Publicado: (2021)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Recommendation for optimal management of severe refractory asthma
por: Morjaria, Jaymin B, et al.
Publicado: (2010)

Sleep deprivation, immune suppression, SARS-CoV-2 infection and sleep disturbances: the death-and-disability loop
por: Pochetti, P., et al.
Publicado: (2022)

Interrelationship Between Obstructive Sleep Apnea Syndrome and Severe Asthma: From Endo-Phenotype to Clinical Aspects
por: Ragnoli, Beatrice, et al.
Publicado: (2021)

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma
por: Plaza, Vicente, et al.
Publicado: (2023)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date
por: Dorey-Stein, Zachariah L, et al.
Publicado: (2021)

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
por: Corren, Jonathan, et al.
Publicado: (2022)

The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022)

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
por: Zoumot, Zaid, et al.
Publicado: (2022)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
por: Laidlaw, Tanya M, et al.
Publicado: (2023)

Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma
por: Lipworth, Brian, et al.
Publicado: (2023)

Exhaled Nitric Oxide as a Biomarker in COPD and Related Comorbidities
por: Malerba, Mario, et al.
Publicado: (2014)

Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol
por: Malerba, Mario, et al.
Publicado: (2014)

Tezepelumab treatment for allergic bronchopulmonary aspergillosis
por: Ogata, Hiroaki, et al.
Publicado: (2023)

Comorbid Insomnia and Obstructive Sleep Apnea (COMISA): Current Concepts of Patient Management
por: Ragnoli, Beatrice, et al.
Publicado: (2021)

The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials
por: Roy, Pooja, et al.
Publicado: (2022)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
Publicado: (2023)

Focus on the Potential Role of Lung Ultrasound in COVID-19 Pandemic: What More to Do?
por: Ragnoli, Beatrice, et al.
Publicado: (2020)

Symptoms and exacerbations in asthma: an apparent paradox?
por: Morjaria, Jaymin B., et al.
Publicado: (2019)

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
por: Menzies-Gow, Andrew, et al.
Publicado: (2023)

Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and outcome
por: Ragnoli, B., et al.
Publicado: (2023)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
por: Alpizar, Sady, et al.
Publicado: (2021)

The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials
por: Lin, Fei, et al.
Publicado: (2023)

Host-Based Treatments for Severe COVID-19
por: Mondini, Lucrezia, et al.
Publicado: (2023)

Dupilumab for cancer-associated refractory pruritus
por: Talmon, Aviv, et al.
Publicado: (2023)

Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis
por: Shaban Abdelgalil, Mahmoud, et al.
Publicado: (2022)

Interrelationship among Obstructive Sleep Apnea, Renal Function and Survival: A Cohort Study
por: Pochetti, Patrizia, et al.
Publicado: (2020)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Supporting healthcare workers on front lines of the Covid-19 fight
por: Malerba, Mario, et al.
Publicado: (2020)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Severe pediatric asthma therapy: Dupilumab
por: Ferrante, Giuliana, et al.
Publicado: (2022)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tmgn85mg886l0b6ed27o8o1518